Compare TISI & RANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TISI | RANI |
|---|---|---|
| Founded | 1973 | 2012 |
| Country | United States | United States |
| Employees | 6800 | N/A |
| Industry | Other Consumer Services | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 101.4M | 106.9M |
| IPO Year | 1995 | 2021 |
| Metric | TISI | RANI |
|---|---|---|
| Price | $26.96 | $0.82 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $7.50 |
| AVG Volume (30 Days) | 28.7K | ★ 623.8K |
| Earning Date | 05-12-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 57.14 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $896,483,000.00 | $1,633,000.00 |
| Revenue This Year | N/A | $274.77 |
| Revenue Next Year | N/A | $79.44 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 5.19 | ★ 58.85 |
| 52 Week Low | $12.34 | $0.45 |
| 52 Week High | $28.05 | $3.87 |
| Indicator | TISI | RANI |
|---|---|---|
| Relative Strength Index (RSI) | 68.14 | 47.00 |
| Support Level | $15.93 | $0.76 |
| Resistance Level | $28.05 | $0.83 |
| Average True Range (ATR) | 1.32 | 0.04 |
| MACD | -0.08 | -0.01 |
| Stochastic Oscillator | 79.01 | 25.62 |
Team Inc provides specialty industrial services, including inspection, engineering assessment, and mechanical repair and remediation required in maintaining high-temperature and high-pressure piping systems and vessels utilized in refining, petrochemicals, and others. The company operates in two segments, Inspection and Heat Treating and Mechanical Services. The Inspection and Heat Treating segment, which generates maximum revenue, provides conventional and non-destructive testing services for the process, pipeline, and power sectors, pipeline integrity management services, and field heat treating services, as well as associated engineering and condition assessment services. Geographically, the company derives its key revenue from the United States, followed by other countries, and Canada.
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.